EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model

Andrew J Fratoni, Alissa M Padgett, Erin M Duffy, David P Nicolau iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Andrew J Fratoni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Pseudomonas aeruginosa, Anti-Bacterial Agents, Tobramycin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Global Antimicrobial Resistance Innovation Fund, UK Department of Health and Social Care, Administration for Strategic Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COMBINE murine neutropenic pneumonia model looks to standardize an important element of preclinical development and provide interlaboratory uniformity. Herein we provide quantitative bacterial density in lung benchmark efficacy data of humanized exposures of meropenem, cefiderocol and tobramycin in plasma and epithelial lining fluid (ELF) against a collection of Klebsiella pneumoniae and Pseudomonas aeruginosa.

Methods

In accordance with the COMBINE protocol, human-simulated regimens (HSRs) based on both plasma and ELF exposures of meropenem, cefiderocol (both as 2 g q8h as 3 h infusions) and tobramycin 7 mg/kg as 30 min infusions were tested against K. pneumoniae and P. aeruginosa isolates. The 24 h change in cfu/lung for each HSR was calculated. Each isolate was tested in duplicate against both the plasma and ELF HSRs on separate experiment days.

Results

Meropenem HSRs demonstrated >1 log10 kill against all P. aeruginosa isolates with MICs of ≤16 mg/L, but only against K. pneumoniae isolates with MICs of ≤2 mg/L as isolates with MICs of >2 mg/L generally harboured carbapenemases. Cefiderocol HSRs uniformly achieved >1 log10 kill against both species at MICs of ≤8 mg/L, with net growth and extensive variability in P. aeruginosa isolates with MICs of 16 mg/L. All tobramycin-susceptible isolates demonstrated >1 log10 kill, while non-susceptible isolates did not. Differences in cfu/lung magnitude between the plasma and ELF HSRs were most pronounced around the clinical breakpoints.

Conclusions

In the COMBINE pneumonia model, administration of plasma and ELF HSRs of meropenem, cefiderocol and tobramycin demonstrated 24 h cfu/lung within reason of expectation given known PK/PD properties and existing clinical breakpoints.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaePseudomonas aeruginosaAnti-Bacterial AgentsTobramycinPseudomonas InfectionsKlebsiella InfectionsCephalosporinsNeutropeniaPneumonia, BacterialPlasmaAnimalsMeropenemDisease Models, AnimalMiceHumansMicrobial Sensitivity TestsCefiderocolFemaleThienamycinsLungBacterial Load

Substanzen

MeropenemAnti-Bacterial AgentsTobramycinCephalosporinsCefiderocolThienamycins

Autor:innen und Institutionen

  • Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
  • CARB-X, Boston, MA, USA.

ORCID-Profile: David P Nicolau

Förderung

  • Global Antimicrobial Resistance Innovation Fund
  • UK Department of Health and Social Care
  • Administration for Strategic Preparedness and Response
  • U.S. Department of Health and Human Services
  • Wellcome
  • Wellcome Trust
  • NIEHS NIH HHS
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Fratoni, A. J., Padgett, A. M., Duffy, E. M., & Nicolau, D. P. (2025). Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf100

Vancouver

Fratoni AJ, Padgett AM, Duffy EM, Nicolau DP. Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf100

BibTeX
@article{Fratoni2025,
  author = {Fratoni, Andrew J and Padgett, Alissa M and Duffy, Erin M and Nicolau, David P},
  title = {Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf100}
}
Kostenlos starten →